Cargando…
Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes
To describe the development and implementation of a new digital health clinical tool (Gynecologic Survivorship Tool [GST]) for symptom management of women surgically treated for gynecologic cancer; to assess its feasibility; and to conduct a retrospective review of the data. MATERIALS AND METHODS: T...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920469/ https://www.ncbi.nlm.nih.gov/pubmed/35239413 http://dx.doi.org/10.1200/CCI.21.00154 |
_version_ | 1784669134260273152 |
---|---|
author | Carter, Jeanne Abu-Rustum, Nadeem R. Saban, Sally Chen, Ling Y. Vickers, Andrew J. Tin, Amy L. Billanti, Gabriela Connors, Nicole A. Broach, Vance Brown, Carol L. Chi, Dennis S. Gardner, Ginger J. Goldfrank, Deborah J. Jewell, Elizabeth L. Leitao, Mario M. Long Roche, Kara C. Mueller, Jennifer J. Sonoda, Yukio Zivanovic, Oliver |
author_facet | Carter, Jeanne Abu-Rustum, Nadeem R. Saban, Sally Chen, Ling Y. Vickers, Andrew J. Tin, Amy L. Billanti, Gabriela Connors, Nicole A. Broach, Vance Brown, Carol L. Chi, Dennis S. Gardner, Ginger J. Goldfrank, Deborah J. Jewell, Elizabeth L. Leitao, Mario M. Long Roche, Kara C. Mueller, Jennifer J. Sonoda, Yukio Zivanovic, Oliver |
author_sort | Carter, Jeanne |
collection | PubMed |
description | To describe the development and implementation of a new digital health clinical tool (Gynecologic Survivorship Tool [GST]) for symptom management of women surgically treated for gynecologic cancer; to assess its feasibility; and to conduct a retrospective review of the data. MATERIALS AND METHODS: The GST was developed on the basis of a comprehensive review of the literature, multidisciplinary expert opinion, and feedback from women with a history of gynecologic cancer. It is composed of 17 questions addressing six main categories—gynecologic health (abnormal bleeding/pain), lymphedema, vaginal/vulvar dryness, sexual health, menopause (hot flushes/sleep difficulties), and bowel/urinary issues. An electronic version using the Memorial Sloan Kettering Cancer Center Engage platform was piloted in two clinics for patients with endometrial or cervical cancer. Health information was generated into clinical summaries and identified concerns for actionable response. Associations of symptom and survey time point were assessed by longitudinal models using generalized estimating equations. RESULTS: From January 1, 2019, to February 29, 2020, 3,357 GST assessments were assigned to 1,405 patients, with a 71% completion rate (90% within 5 minutes). Sixty-eight percent were performed at home via a patient portal, 32% at follow-ups using a clinic iPad. The most common symptoms were bowel problems, swelling/fluid, pain during examination, vaginal or vulvar dryness, and vaginal bleeding. Implementation challenges included improving patient compliance and ensuring that reports were reviewed by all clinical teams. We developed screening e-mails detailing patients whose assessments were due, planned training sessions for multidisciplinary teams, and incorporated feedback on methods for reviewing symptoms reports. CONCLUSION: The GST demonstrated feasibility, a high completion rate, and minimal time commitment. It was an effective electronic reporting mechanism for patients, enabling the medical team to develop specific strategies for alleviating bothersome symptoms during follow-up. |
format | Online Article Text |
id | pubmed-8920469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-89204692023-03-03 Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes Carter, Jeanne Abu-Rustum, Nadeem R. Saban, Sally Chen, Ling Y. Vickers, Andrew J. Tin, Amy L. Billanti, Gabriela Connors, Nicole A. Broach, Vance Brown, Carol L. Chi, Dennis S. Gardner, Ginger J. Goldfrank, Deborah J. Jewell, Elizabeth L. Leitao, Mario M. Long Roche, Kara C. Mueller, Jennifer J. Sonoda, Yukio Zivanovic, Oliver JCO Clin Cancer Inform Original Reports To describe the development and implementation of a new digital health clinical tool (Gynecologic Survivorship Tool [GST]) for symptom management of women surgically treated for gynecologic cancer; to assess its feasibility; and to conduct a retrospective review of the data. MATERIALS AND METHODS: The GST was developed on the basis of a comprehensive review of the literature, multidisciplinary expert opinion, and feedback from women with a history of gynecologic cancer. It is composed of 17 questions addressing six main categories—gynecologic health (abnormal bleeding/pain), lymphedema, vaginal/vulvar dryness, sexual health, menopause (hot flushes/sleep difficulties), and bowel/urinary issues. An electronic version using the Memorial Sloan Kettering Cancer Center Engage platform was piloted in two clinics for patients with endometrial or cervical cancer. Health information was generated into clinical summaries and identified concerns for actionable response. Associations of symptom and survey time point were assessed by longitudinal models using generalized estimating equations. RESULTS: From January 1, 2019, to February 29, 2020, 3,357 GST assessments were assigned to 1,405 patients, with a 71% completion rate (90% within 5 minutes). Sixty-eight percent were performed at home via a patient portal, 32% at follow-ups using a clinic iPad. The most common symptoms were bowel problems, swelling/fluid, pain during examination, vaginal or vulvar dryness, and vaginal bleeding. Implementation challenges included improving patient compliance and ensuring that reports were reviewed by all clinical teams. We developed screening e-mails detailing patients whose assessments were due, planned training sessions for multidisciplinary teams, and incorporated feedback on methods for reviewing symptoms reports. CONCLUSION: The GST demonstrated feasibility, a high completion rate, and minimal time commitment. It was an effective electronic reporting mechanism for patients, enabling the medical team to develop specific strategies for alleviating bothersome symptoms during follow-up. Wolters Kluwer Health 2022-03-03 /pmc/articles/PMC8920469/ /pubmed/35239413 http://dx.doi.org/10.1200/CCI.21.00154 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Reports Carter, Jeanne Abu-Rustum, Nadeem R. Saban, Sally Chen, Ling Y. Vickers, Andrew J. Tin, Amy L. Billanti, Gabriela Connors, Nicole A. Broach, Vance Brown, Carol L. Chi, Dennis S. Gardner, Ginger J. Goldfrank, Deborah J. Jewell, Elizabeth L. Leitao, Mario M. Long Roche, Kara C. Mueller, Jennifer J. Sonoda, Yukio Zivanovic, Oliver Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes |
title | Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes |
title_full | Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes |
title_fullStr | Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes |
title_full_unstemmed | Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes |
title_short | Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes |
title_sort | gynecologic survivorship tool: development, implementation, and symptom outcomes |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920469/ https://www.ncbi.nlm.nih.gov/pubmed/35239413 http://dx.doi.org/10.1200/CCI.21.00154 |
work_keys_str_mv | AT carterjeanne gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT aburustumnadeemr gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT sabansally gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT chenlingy gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT vickersandrewj gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT tinamyl gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT billantigabriela gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT connorsnicolea gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT broachvance gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT browncaroll gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT chidenniss gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT gardnergingerj gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT goldfrankdeborahj gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT jewellelizabethl gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT leitaomariom gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT longrochekarac gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT muellerjenniferj gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT sonodayukio gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes AT zivanovicoliver gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes |